Capricor Therapeutics (CAPR) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kamada (KMDA) has outperformed Capricor Therapeutics (CAPR) over the past year, gaining 18.6% versus a gain of 8.0%. Over five years, CAPR leads with a +104.5% price change compared with +49.7% for KMDA. Capricor Therapeutics is the larger company by market cap ($470.9 million vs $455.3 million), about 1.0 times the size.
Kamada pays a dividend yielding 3.17%, while Capricor Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | KMDA |
|---|---|---|
| Share price | $8.10 | $7.89 |
| Market cap | $470.93M | $455.33M |
| 1-day change | +4.52% | -2.71% |
| YTD return | -71.93% | +11.76% |
| 1-year return | +8.00% | +18.65% |
| 5-year return | +104.55% | +49.72% |
| P/E ratio (TTM) | — | 20.76 |
| Forward P/E | — | 13.68 |
| EPS (TTM) | $-2.45 | $0.38 |
| Dividend yield | 0.00% | 3.17% |
| Annual dividend | $0.00 | $0.25 |
| 52-week high | $40.37 | $9.35 |
| 52-week low | $2.96 | $6.55 |
| Distance from 52-week high | -79.94% | -15.61% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +233.33% | +71.10% |
| Average volume | 6.85M | 118.04K |
| Shares outstanding | 58.14M | 57.71M |
| Employees | 231 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMDA has outperformed CAPR by 10.6 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (3.17% vs 0.00%).
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
CAPR vs KMDA FAQ
Which is bigger, Capricor Therapeutics or Kamada?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $470.93M compared with $455.33M for Kamada (KMDA).
Which stock has performed better over the past year, CAPR or KMDA?
KMDA returned +18.65% over the past 12 months, compared with +8.00% for CAPR (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Capricor Therapeutics or Kamada?
Kamada pays a dividend yielding 3.17%, while Capricor Therapeutics does not currently pay a regular dividend.
Are Capricor Therapeutics and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.